Johnson & Johnson appears to exit LAA closure market, selling heart tech to new startup - Cardiovascular Business
Johnson & Johnson appears to exit LAA closure market, selling heart tech to new startup Cardiovascular Business
Johnson & Johnson Company News
Johnson & Johnson requires providers to share claims data to get 340B discounts - Healthcare Dive
Johnson & Johnson requires providers to share claims data to get 340B discounts Healthcare Dive
Johnson & Johnson Targets Double-Digit Growth as STELARA Faces Biosimilar Competition - Yahoo Finance
Johnson & Johnson Targets Double-Digit Growth as STELARA Faces Biosimilar Competition Yahoo Finance
J&J sells Laminar LAA closure assets it bought 3 years ago - MedTech Dive
J&J sells Laminar LAA closure assets it bought 3 years ago MedTech Dive
Governor Shapiro Secures Over $1 Billion Investment from Johnson & Johnson to Build New Cancer-Fighting Manufacturing Facility in Montgomery County, Creating More Than 500 New Jobs - PA Department of Community & Economic Development (.gov)
Governor Shapiro Secures Over $1 Billion Investment from Johnson & Johnson to Build New Cancer-Fighting Manufacturing Facility in Montgomery County, Creating More Than 500 New Jobs PA Department of Community & Economic Development (.gov)
J&J looking to offload orthopedics unit in $20B deal to Apollo: Bloomberg - fiercebiotech.com
J&J looking to offload orthopedics unit in $20B deal to Apollo: Bloomberg fiercebiotech.com
J&J in talks to sell DePuy Synthes to Apollo for $20 billion - qz.com
J&J in talks to sell DePuy Synthes to Apollo for $20 billion qz.com
Johnson & Johnson MedTech reportedly could sell DePuy Synthes to Apollo - MassDevice
Johnson & Johnson MedTech reportedly could sell DePuy Synthes to Apollo MassDevice
Johnson & Johnson in talks to sell its orthopedic division - medwatch.com
Johnson & Johnson in talks to sell its orthopedic division medwatch.com
Apollo Global Management in Talks to Acquire J&J's DePuy Synthes - Medical Device and Diagnostic industry
Apollo Global Management in Talks to Acquire J&J's DePuy Synthes Medical Device and Diagnostic industry
Monthly Paydays vs. Compound Growth: Why JNJ Beats O for Long-Term Retirees - 24/7 Wall St.
Monthly Paydays vs. Compound Growth: Why JNJ Beats O for Long-Term Retirees 24/7 Wall St.
Abiomed Gets Benefit Plan Exemption for Johnson & Johnson Deal - Bloomberg Law News
Abiomed Gets Benefit Plan Exemption for Johnson & Johnson Deal Bloomberg Law News
Apollo Reportedly In Talks To Acquire Johnson & Johnson’s DePuy Synthes For Around $20 Billion - Pulse 2.0
Apollo Reportedly In Talks To Acquire Johnson & Johnson’s DePuy Synthes For Around $20 Billion Pulse 2.0
Apollo rumoured to be eyeing $20bn takeover of J&J’s orthopaedics business - Medical Device Network
Apollo rumoured to be eyeing $20bn takeover of J&J’s orthopaedics business Medical Device Network
Johnson & Johnson Tags Jacqueline Henderson as Company Group Chair, Vision - VisionMonday.com
Johnson & Johnson Tags Jacqueline Henderson as Company Group Chair, Vision VisionMonday.com
The $5.5 Billion Decision: How Johnson & Johnson Chose to Walk Away From a Fight It Claims to Have Been Winning - lawnews.co.uk
The $5.5 Billion Decision: How Johnson & Johnson Chose to Walk Away From a Fight It Claims to Have Been Winning lawnews.co.uk
Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September - Johnson & Johnson
Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September Johnson & Johnson
Apollo and J&J Face a High-Stakes Orthopedics Deal - Yahoo Finance
Apollo and J&J Face a High-Stakes Orthopedics Deal Yahoo Finance
Zacks Investment Ideas feature highlights: Johnson & Johnson, Coca-Cola and Exxon Mobil - Yahoo Finance
Zacks Investment Ideas feature highlights: Johnson & Johnson, Coca-Cola and Exxon Mobil Yahoo Finance
Johnson & Johnson Eyes High-End MedTech Growth as Cardiovascular Takes Center Stage - Yahoo Finance
Johnson & Johnson Eyes High-End MedTech Growth as Cardiovascular Takes Center Stage Yahoo Finance
Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided? - Trefis
Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided? Trefis
Johnson & Johnson Stock: Is JNJ Outperforming the Consumer Staples Sector? - Yahoo Finance
Johnson & Johnson Stock: Is JNJ Outperforming the Consumer Staples Sector? Yahoo Finance
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder - businesswire.com
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder businesswire.com
Johnson & Johnson Advances Spin-Off and Sale in Parallel as Orthopedics Business Valued at Nearly $20 Billion - NAI500
Johnson & Johnson Advances Spin-Off and Sale in Parallel as Orthopedics Business Valued at Nearly $20 Billion NAI500
Johnson & Johnson Replaced $913 Million In Lost Sales With $2.4 Billion In New Ones - But Kept Less Than Half - Seeking Alpha
Johnson & Johnson Replaced $913 Million In Lost Sales With $2.4 Billion In New Ones - But Kept Less Than Half Seeking Alpha
Johnson & Johnson (NYSE:JNJ) Steps Into the healthcare stocks Spotlight Today? - Kalkine Media
Johnson & Johnson (NYSE:JNJ) Steps Into the healthcare stocks Spotlight Today? Kalkine Media
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. - The Motley Fool
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. The Motley Fool
Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect. - 24/7 Wall St.
Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect. 24/7 Wall St.
Shockwave to Claim the Johnson & Johnson Name - Medical Device and Diagnostic industry
Shockwave to Claim the Johnson & Johnson Name Medical Device and Diagnostic industry
US FDA expands approval for J&J's drug for rare blood disorder - Reuters
US FDA expands approval for J&J's drug for rare blood disorder Reuters
Johnson & Johnson names new vice president for litigation - Reuters
Johnson & Johnson names new vice president for litigation Reuters
Why Procter & Gamble’s Quieter Dividend Outpaces Johnson & Johnson’s Growth Story - 24/7 Wall St.
Why Procter & Gamble’s Quieter Dividend Outpaces Johnson & Johnson’s Growth Story 24/7 Wall St.
What Is Changing the Conversation Around Johnson & Johnson (JNJ)? - Kalkine Media
What Is Changing the Conversation Around Johnson & Johnson (JNJ)? Kalkine Media
Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable? - Yahoo Finance
Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable? Yahoo Finance
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool
Johnson & Johnson Just Got a Big FDA Win - The Motley Fool
Johnson & Johnson Just Got a Big FDA Win The Motley Fool
Johnson & Johnson Publishes New Future of Digital Surgery Report to Help Define the Emerging Field of Surgical Intelligence - Johnson & Johnson
Johnson & Johnson Publishes New Future of Digital Surgery Report to Help Define the Emerging Field of Surgical Intelligence Johnson & Johnson
What’s Behind Johnson & Johnson (NYSE:JNJ) Market Attention? - Kalkine Media
What’s Behind Johnson & Johnson (NYSE:JNJ) Market Attention? Kalkine Media
Johnson & Johnson Is Near a Record High. Is There Still Room to Run? - 24/7 Wall St.
Johnson & Johnson Is Near a Record High. Is There Still Room to Run? 24/7 Wall St.
Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System - Johnson & Johnson
Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System Johnson & Johnson